2R-DDAIP Enantiomer for Transdermal Drug Permeation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal drug delivery methods face challenges in penetrating the skin's barrier effectively, and existing skin penetration enhancers may irritate or destabilize drugs, while enantiomerically enriched forms of dodecyl 2-(N,N-dimethylamino)-propionate (DDAIP) have shown limited stereoselectivity in enhancing drug transport.
Innovation Solution
The use of enantiomerically enhanced DDAIP in the 2R-configuration, with enantiomeric purities of at least 70%, as a free base or salt form, to facilitate the transport of pharmaceutically active compounds across biological membranes, particularly demonstrated with lansoprazole, showing enhanced activity compared to racemic and S-enantiomeric forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If racemic DDAIP is used as a skin penetration enhancer, then drug absorption is enhanced, but stereoselectivity is limited and adverse effects may occur
Solution Approach 1:
The racemic mixture of DDAIP is separated into individual enantiomers (R-DDAIP and S-DDAIP) through chiral resolution. This segmentation allows selection of the specific R-enantiomer that demonstrates superior stereoselectivity and enhanced drug absorption properties, eliminating the limitations of using the mixed racemic form.
Solution Approach 2:
The enantiomeric purity parameter is changed from 50% (racemic mixture) to predominantly R-configurated form. This parameter change in stereochemical composition results in enhanced stereoselectivity and improved drug penetration efficacy while reducing adverse effects.
2Productivity
If skin penetration enhancers are used to overcome the skin barrier, then drug flux across skin increases, but skin irritation and drug stability may be compromised
Solution Approach 1:
The chemical structure parameter is modified by selecting the specific R-enantiomer of DDAIP, which exhibits enhanced penetration capability with reduced skin irritation. The stereoselective properties of the R-configurated molecule provide improved therapeutic index by maintaining efficacy while reducing adverse effects on skin tissue.
Solution Approach 2:
The patent utilizes the biodegradable nature of DDAIP, which is metabolized to naturally occurring amino acids in the body. This allows the use of an effective penetration enhancer that does not accumulate and causes minimal long-term harm to skin tissue.
3Productivity
If penetration enhancers are used to improve drug absorption, then therapeutic levels are achieved, but physical stability of dosage form may be affected
Solution Approach 1:
The use of the R-enantiomer with specific stereochemical parameters improves compatibility with dosage form components. The enhanced stereoselectivity of the pure enantiomer form provides better physical stability in topical formulations compared to racemic mixtures, reducing phase separation and maintaining formulation integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 2R-DDAIP significantly increases the oral uptake of lansoprazole into the bloodstream, demonstrating enhanced penetration efficacy without adverse effects on skin stability or cosmetic quality, with R-DDAIP being 2.7 times more effective than S-DDAIP in enhancing drug absorption.
Implementation Method 1
The 2R-DDAIP exhibits enhanced activity vis-a-vis facilitating transport of materials (e.g., a pharmaceutically active compound comprising lansoprazole) across a biological membrane or tissue
Data Source
Figure 1
AI summary
2R-dodecyl 2-(N,N dimethylamino)-propionate (R-DDAIP) provides an unexpectedly improved activity in facilitating transport of a pharmaceutically active compound across biological membranes and tissues, compared to S-DDAIP of the same enantiomeric purity, or racemic DDAIP. Purified S-DDAIP is also provided.